Amplify Weight Loss Drug ... (THNR)
NYSEArca: THNR
· Echtzeitkurs · USD
27.25
+1.04 (3.97%)
Zum Schluss: Aug 18, 2026, 10:57 AM
Amplify Weight Loss Drug & Treatment ETF (THNR) ETF Price, Holdings & Analysis
3.97% (1D)
| Geld | 10.64 |
| Marktkapitalisierung | n/a |
| Fondsvermögen | 5.07 Mio |
| NAV | 26.22 |
| Beta | k.A. |
| EPS (ttm) | k.A. |
| PE Ratio (ttm) | 19.74 |
| Ausstehende Anteile | k.A. |
| Auflagedatum | May 20, 2024 |
| Brief | 42.07 |
| Volumen | 4,637 |
| Ø Vol. (20D) | 2,067 |
| Eröffnung | 26.39 |
| Vortagesschluss | 26.21 |
| Tagesspanne | 26.39 - 26.46 |
| 52-Wk Range | 22.63 - 27.28 |
| Positionen | k.A. |
| Kostenquote | 0.59% |
Über THNR
The fund's manager invests at least 80% of its net assets (plus borrowings for investment purposes) in securities that comprise the index. The index is comprised of global companies expected to economically benefit from weight loss drug development. The index includes pharmaceutical manufacturers, manufacturers of combination therapies and telehealth providers who provide access to Amylin agonists and analogs or GLP-1 agonists and analogs, including dual GLP-1 agonists and analogs. The fund is non-diversified.
Anlageklasse Equity
Tickersymbol THNR
Auflagedatum May 20, 2024
Anbieter Amplify Etfs
Website Fonds-Homepage
Börse NYSEArca
Top 10 Positionen 61.60% insgesamt
| Name | Symbol | Gewicht |
|---|---|---|
| Novo Nordisk As Adr | NVO | 9.70% |
| Eli Lilly And Co | LLY | 8.92% |
| Regeneron Pharmaceut... | REGN | 6.03% |
| Cspc Pharmaceutical ... | 1093.HK | 5.52% |
| Arrowhead Pharmaceut... | ARWR | 5.34% |
| Innovent Biologics I... | 1801.HK | 5.34% |
| Amgen Inc | AMGN | 5.25% |
| Abbvie Inc | ABBV | 5.24% |
| Roche Holding Ag Ord... | ROP.SW | 5.20% |
| Merck & Co Inc | MRK | 5.06% |
Dividenden Dividendenrendite 1.52%
| Ex-Dividende | Betrag | Zahldatum |
|---|---|---|
| Dec 30, 2025 | $0.4130 | k.A. |
| Dec 30, 2024 | $0.2200 | k.A. |
Seite 1 von 2